Selinexor + Pacritinib for Myelofibrosis

This trial explores a new treatment combination for myelofibrosis, a bone marrow disorder that causes severe anemia (low red blood cells) and thrombocytopenia (low platelet count). Researchers are testing two drugs, pacritinib and selinexor, to assess their safety and effectiveness in patients who have not yet tried JAK inhibitors, a common treatment for this condition. This trial suits those diagnosed with myelofibrosis who experience symptoms like anemia or an enlarged spleen. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people, offering patients a chance to contribute to important findings.

The trial protocol does not specify if you must stop taking your current medications. However, you cannot use any MF-directed therapy (except hydroxyurea) within two weeks before starting the trial. It's best to discuss your current medications with the trial team.

A previous study found pacritinib to be as safe as, or even safer than, treatments like ruxolitinib, suggesting pacritinib might offer a safer alternative to some current options. Early research on selinexor indicates it is safe and effective for treating myelofibrosis, though further information is needed for confirmation. Another study showed that 79% of patients taking selinexor experienced a reduction in spleen size, indicating potential effectiveness.

Most treatments for myelofibrosis focus on managing symptoms or reducing spleen size, often using medications like JAK inhibitors. However, the combination of Selinexor and Pacritinib is unique because it targets the disease differently. Selinexor works by inhibiting the nuclear export of tumor suppressor proteins, helping to restore their normal function, while Pacritinib is a JAK2/FLT3 inhibitor designed to manage symptoms without significantly lowering platelet counts. This dual approach offers a promising new mechanism that could improve effectiveness and safety for patients with myelofibrosis, providing an exciting potential advancement over current therapies.

Research has shown that combining selinexor and pacritinib may offer promise for treating myelofibrosis, particularly in patients who have not yet tried JAK inhibitors. Earlier studies demonstrated that selinexor, when combined with other treatments, significantly reduced spleen size in about 50% of patients. Used alone, selinexor helped 79% of patients achieve a 35% reduction in spleen size. In this trial, participants will initially receive pacritinib monotherapy. If they qualify, selinexor will be added to their regimen. Researchers are studying pacritinib for its potential to improve low red blood cell and platelet counts. Together, these drugs aim to provide a new way to manage myelofibrosis symptoms effectively.¹²⁵⁶⁷